$FLAC News
Last published 3y ago
- 3y agoFLACNAMSNAMSWNewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease PatientsGlobeNewswire-- Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on November 22, 2022 -- --
- 3y agoFLACFLACUFrazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holding B.V.Business WireFrazier Lifesciences Acquisition Corporation (NASDAQ:FLAC) ("FLAC"), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, announced today that its shareholders voted to approve
- 4y agoALPNANABFLACPHATPhathom Pharmaceuticals Appoints Dr. James Topper to its Board of DirectorsGlobeNewswireFLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the
- 4y agoFLACNewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic DiseasesBusiness Wire– Leading institutional investors commit approximately $235 million through an oversubscribed and upsized private investment in public equity ("PIPE") led by Frazier Healthcare Partners and Bain Capital Life Sciences – – Total proceeds expected
- 5y agoFLACISEEKRYSRCKT+4Frazier Healthcare Partners Announces Several Promotions on Life Sciences TeamBusiness WireFrazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabra